Dr Reddy's Laboratories Q3 results beat estimates; should you buy, sell, or hold?

Pharmaceutical major Dr Reddy's Laboratories posted consolidated net profit for the third quarter at Rs 1,378.9 crore Year-on-Year (YoY), which was estimated at Rs 1,310 crore by Zee Business research team.

Its revenue stood at Rs 7,237 crore against Rs 6,790 crore YoY, which was estimated at Rs 6,914 crore.

Here's how brokerages view Dr Reddy's Laboratories:

CLSA downgrades to 'underperform'

Raises the target to Rs 6,080 from Rs 5,100.

Raises the target to Rs 5,900 from Rs 5,825.

Goldman Sachs continues with a 'neutral' rating

The brokerage gives a target of Rs 5,802.

Nomura iterates a 'neutral' rating

Citi maintains 'sell'

Gives a target of Rs 5,290.

Jefferies continues with an 'underperform' stance

The brokerage gives a target of Rs 5,040.

Macquarie iterates 'outperform'

Gives a target of Rs 6,400.

Image source | Pexels